Immatics N.V. (IMTX) News
Filter IMTX News Items
IMTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IMTX News Highlights
- For IMTX, its 30 day story count is now at 4.
- Over the past 27 days, the trend for IMTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- CELL are the most mentioned tickers in articles about IMTX.
Latest IMTX News From Around the Web
Below are the latest news stories about IMMATICS NV that investors may wish to consider to help them evaluate IMTX as an investment opportunity.
Immatics N.V. (NASDAQ:IMTX) is definitely on the radar of institutional investors who own 47% of the companyKey Insights Significantly high institutional ownership implies Immatics' stock price is sensitive to their trading... |
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of DirectorsAppointment effective as of September 14, 2023;Zeev Bronfeld to retire from the Board of Directors |
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology TherapeuticsModerna, Inc. (NASDAQ:MRNA, "Moderna") and Immatics N.V. (NASDAQ:IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need. |
Those who invested in Immatics (NASDAQ:IMTX) three years ago are up 27%By buying an index fund, you can roughly match the market return with ease. But if you pick the right individual... |
Immatics Announces Second Quarter 2023 Financial Results and Business UpdatePhase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting PRAMEACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on 11 heavily pre-treated patients in Phase 1b dose expansion Cohort A with median duration of response not reached at a median follow-up time of 8.5 months at data cut-off; next update in 4Q 2023Bristol Myers Squibb exercised first opt-in into |
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid TumorsTCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinicPatient enrollment for IMA402 Phase 1/2 trial underwayThe trial will evaluate safety, tolerability, and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumorsFirst clinical data expected in 2024 Tuebingen, Germany and Houston, Texas, August 10, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the disc |
Immatics Announces $35 Million Equity Investment from Bristol Myers SquibbTuebingen, Germany and Houston, TX, July 24, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that Bristol Myers Squibb (NYSE: BMY) has made a $35 million equity investment in Immatics. Bristol Myers Squibb purchased 2,419,818 ordinary shares in a private placement transaction at a subscription price per share of $14.461. Additionally, Bristol Myers Squ |
Immatics Announces First Quarter 2023 Financial Results and Business UpdateACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on heavily pre-treated 11 patients in Phase 1b dose expansion Cohort A with median duration of response not reached at a median follow-up time of 8.5 months at data cut-offObjective responses observed across multiple tumor types including checkpoint-refractory cutaneous melanoma, platinum-resistant ovarian cancer, uveal melanoma, head and neck cancer and synovial sarcomaCohort A IMA203 monoth |
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAMECompany to host conference call today, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203 TCR-T monotherapy against PRAME Objective response rate (ORR): 64% (7/11) initial ORR at week 6 and 67% (6/9) confirmed ORR at month 3Median duration of response not reached at median follow-up time of 8.5 months at data cut-offObjective responses independent of solid tumor type at low, medium and hi |
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic CollaborationBristol Myers Squibb exercised its first option and entered into a global license agreement with Immatics for the most advanced TCR-T product candidate from the companies’ ongoing collaboration to develop four TCR-based adoptive cell therapies targeting solid tumors Immatics to receive an option payment of $15 million and is eligible for additional up to $490 million in milestone payments in addition to tiered royalties on net sales of the product Tuebingen, Germany & Houston, May 1, 2023 – Imma |